Pilot study evaluating the feasibility of endoscopy guided fiducial marker placement for rectal cancer. - Endoscopy guided fiducial marker placement for rectal cancer.

Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年6月11日

适应症

试验速览

暂无简介。

•Histologically proven diagnosis of primary rectal adenocarcinoma
•Treatment plan:
•o 5x5 Gray (Gy) neoadjuvant radiotherapy followed by TME
•* cT1-3N1 / cT3N0 with extramural invasion >5 mm
•* Distance to mesorectal fascia >1 mm
•o Chemoradiation consisting of 25 x 1,8 Gy combined with Capecitabine 825 mg/m2 twice daily followed by TME
•* cT4 / cT2-3 with distance to mesorectal fascia <=1 mm
•* cN2 / extramesorectal pathological lymph nodes
•o 5x5 Gy RT followed by chemotherapy (with or without a subsequent TME)
•* rectal cancer with resectable liver metastases
•Written informed consent

•Coagulopathy (prothrombin time < 50% of control; partial thromboplastin time > 50 seconds) or anticoagulantia (marcoumar, sintrom or new oral anticoagulants) that cannot be stopped
•Prior pelvic irradiation or surgery that may affect the placement of the markers
•World health organization performance status 3-4
•Pregnant women
•Patients who underwent a hip replacement
•Patients with a contraindication for MRI (e.g. pacemaker, metallic foreign body in the eye, cerebral aneurysm clips, claustrophobia)

发起方

Antoni van Leeuwenhoek Ziekenhuis